Thomas J.
- Country
- France
- Department
- Service de Néphrologie
Research Overview
- Phase III Randomized Double‑Blind Placebo‑Controlled Trial of Elecoglipron (AZD5004) on Renal Decline and Mortality in Adults with Chronic Kidney Disease
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy
- Evaluation of Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sibeprenlimab in Patients with Immunoglobulin A Nephropathy
Data & Insights
Has run more than one trial at 82 of 317 partner sites.
Specializations
Primary Nephropathies
The investigator specializes in treating IgA Nephropathy, conducting research into innovative therapeutic approaches for this common form of glomerulonephritis. Their work includes evaluating novel treatments such as sibeprenlimab and atacicept for managing this condition.
- IgA Nephropathy management
- Proteinuria reduction strategies
- Long-term disease monitoring
Genetic Kidney Disorders
The investigator focuses on rare genetic kidney conditions, including APOL1-mediated kidney disease and Alport Syndrome. Their research encompasses innovative therapeutic approaches for these hereditary conditions, particularly focusing on proteinuria management.
- APOL1-mediated nephropathy
- Alport Syndrome treatment
- Genetic kidney disease progression
Glomerular Diseases
The investigator has extensive experience in treating focal segmental glomerulosclerosis and lupus nephritis. Their research includes evaluation of novel compounds for managing these complex kidney disorders.
- FSGS therapeutic approaches
- Lupus nephritis management
- Glomerular disease interventions
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.